GLP-1 Drugs Like Ozempic: New Study Reveals who Benefits Most
New research suggests that why you overeat may determine how well you respond to popular weight loss drugs like Ozempic and Wegovy. These GLP-1 agonists have been hailed as “wonder drugs” for their ability to lower blood sugar and promote weight loss, but their effectiveness isn’t worldwide. A new study published in Frontiers in Clinical Diabetes and Healthcare sheds light on this variability, identifying key eating behaviors that predict treatment success.
The Study: Unpacking Eating Motivations
Researchers at Kyoto University in Japan followed 92 participants wiht type 2 diabetes throughout their first year on GLP-1 agonist therapy. They meticulously tracked changes in body weight, composition, diet, and key health markers like blood glucose and cholesterol. Crucially, the study also delved into the reasons behind participants’ overeating, categorizing them into three distinct patterns:
* Emotional Eating: Consuming food in response to negative emotions.
* External Eating: Eating triggered by external cues like the sight or smell of appealing food.
* Restrained Eating: Actively restricting food intake to lose weight (which, paradoxically, can sometimes lead to disordered eating).
Key Findings: External Cues vs. Emotional Drivers
The results revealed a important correlation between eating behavior and treatment outcomes. Individuals who overate in response to external stimuli – the allure of flavorful food – experienced greater and more sustained benefits from GLP-1 agonists. They saw significant reductions in body weight, cholesterol levels, and body fat percentage over the year-long study period.
Conversely, the drugs were less effective for those whose overeating stemmed from emotional reasons.
“pre-treatment assessment of eating behavior patterns may help predict who will benefit most from GLP-1 receptor agonist therapy,” explained senior author Daisuke Yabe, a professor at Kyoto University. “GLP-1 receptor agonists are effective for individuals who experience weight gain or elevated blood glucose levels due to overeating triggered by external stimuli.Though, their effectiveness is less expected in cases where emotional eating is the primary cause.”
what This Means for Patients
This research underscores the importance of a personalized approach to weight management.GLP-1 agonists aren’t a one-size-fits-all solution. Understanding why a patient overeats could be crucial in determining whether these drugs are likely to be effective.
while participants overall experienced positive changes – including statistically significant weight loss and improved cholesterol – the study highlights that addressing the underlying psychological drivers of eating is essential for long-term success.
Source: Frontiers in Clinical Diabetes and Healthcare.[https://linkmediaoutreachmeltwatercom/ls/click?upn=u001MdVeKMXe-2Bu-2BITFqnYKpwpYrG9aSJSXpvhXXGDX3ObsnegShxWQwqHODanc6H738E-2Bo8T8fCv1nPHsNZ52emeEe-2BHuu-2FLxRs7AQVij7YVTC3A2m0tVYz0-2FTsrQ6P5OQMI-2BEBR5flHCMVKYVhSKbIKJoTfpIDJePzLuuFb0wmYz4s-3DD9Nu_yB8pNXz8iKogugC36vxXF8jd5h9-2FtEOBOP0lptxNzsvZWv-2BQhQD6pakquPhDw34AAcftjWXS1UdOtUBR4U0ym99LGcTup4DuQ9qw8a6GqxwcbCmXo2ztgoMdqoTzqBpjswa4BKOOqLXZk5iwEJ1uf[https://linkmediaoutreachmeltwatercom/ls/click?upn=u001MdVeKMXe-2Bu-2BITFqnYKpwpYrG9aSJSXpvhXXGDX3ObsnegShxWQwqHODanc6H738E-2Bo8T8fCv1nPHsNZ52emeEe-2BHuu-2FLxRs7AQVij7YVTC3A2m0tVYz0-2FTsrQ6P5OQMI-2BEBR5flHCMVKYVhSKbIKJoTfpIDJePzLuuFb0wmYz4s-3DD9Nu_yB8pNXz8iKogugC36vxXF8jd5h9-2FtEOBOP0lptxNzsvZWv-2BQhQD6pakquPhDw34AAcftjWXS1UdOtUBR4U0ym99LGcTup4DuQ9qw8a6GqxwcbCmXo2ztgoMdqoTzqBpjswa4BKOOqLXZk5iwEJ1uf[https://linkmediaoutreachmeltwatercom/ls/click?upn=u001MdVeKMXe-2Bu-2BITFqnYKpwpYrG9aSJSXpvhXXGDX3ObsnegShxWQwqHODanc6H738E-2Bo8T8fCv1nPHsNZ52emeEe-2BHuu-2FLxRs7AQVij7YVTC3A2m0tVYz0-2FTsrQ6P5OQMI-2BEBR5flHCMVKYVhSKbIKJoTfpIDJePzLuuFb0wmYz4s-3DD9Nu_yB8pNXz8iKogugC36vxXF8jd5h9-2FtEOBOP0lptxNzsvZWv-2BQhQD6pakquPhDw34AAcftjWXS1UdOtUBR4U0ym99LGcTup4DuQ9qw8a6GqxwcbCmXo2ztgoMdqoTzqBpjswa4BKOOqLXZk5iwEJ1uf[https://linkmediaoutreachmeltwatercom/ls/click?upn=u001MdVeKMXe-2Bu-2BITFqnYKpwpYrG9aSJSXpvhXXGDX3ObsnegShxWQwqHODanc6H738E-2Bo8T8fCv1nPHsNZ52emeEe-2BHuu-2FLxRs7AQVij7YVTC3A2m0tVYz0-2FTsrQ6P5OQMI-2BEBR5flHCMVKYVhSKbIKJoTfpIDJePzLuuFb0wmYz4s-3DD9Nu_yB8pNXz8iKogugC36vxXF8jd5h9-2FtEOBOP0lptxNzsvZWv-2BQhQD6pakquPhDw34AAcftjWXS1UdOtUBR4U0ym99LGcTup4DuQ9qw8a6GqxwcbCmXo2ztgoMdqoTzqBpjswa4BKOOqLXZk5iwEJ1uf
